Menu Search
Equities

Kaken Pharmaceutical Co Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
KKPCF:PKL

Kaken Pharmaceutical Co Ltd

Actions
  • Price (USD)26.00
  • Today's Change0.00 / 0.00%
  • Shares traded200.00
  • 1 Year change--
  • Beta0.1277
Data delayed at least 15 minutes, as of Jan 13 2026 18:05 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Kaken Pharmaceutical Co Ltd is a Japan-based company primarily engaged in the pharmaceutical and real estate businesses. The Company has two business segments. The Pharmaceutical Business segment is primarily engaged in the manufacture and sale of pharmaceuticals, medical equipment, and agricultural chemicals. The Real Estate Business segment is primarily engaged in the rental of real estate related to Bunkyo Green Court.

  • Revenue in JPY (TTM)75.66bn
  • Net income in JPY-3.83bn
  • Incorporated1948
  • Employees1.13k
  • Location
    Kaken Pharmaceutical Co Ltd20F, Bunkyo Green Court Center Office2-28-8, HonkomagomeBUNKYO-KU 113-8650JapanJPN
  • Phone+81 359775001
  • Fax+81 359775131
  • Websitehttps://www.kaken.co.jp
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.